As part of our ongoing series here at The Acquirer’s Multiple, each week we focus on one of the stocks from our Stock Screeners, and why it’s a ‘buy’ based on key fundamentals.
One of the cheapest stocks in our Stock Screeners is:
Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
A quick look at the share price history (below) over the past twelve months shows that the price is down 28.40%. Here’s why the company is undervalued.
Key Stats
Market Cap: $102.89 Billion
Enterprise Value: $132.07 Billion
Operating Earnings
Operating Earnings: $8.45 Billion
Acquirer’s Multiple
Acquirer’s Multiple: 15.60
Free Cash Flow (TTM)
Free Cash Flow: $12.65 Billion
FCF/EV Yield %:
FCF/EV Yield: 12.30
Shareholder Yield %:
Shareholder Yield: 9.60
Other Indicators
Piotroski F Score: 6.00
Altman Z-Score (TTM): 2.297
ROA (5 Year Avge%): 9
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:
